Literature DB >> 12578305

HHV 8 seroprevalence and transmission within Albanian family groups.

R Graffeo1, S Ranno, S Marchetti, N Capodicasa, A M Schito, L Fuga, R Amico, P Cattani, G Fadda.   

Abstract

The recently discovered Human Herpesvirus 8 (HHV 8) is associated with all clinical forms of Kaposi's sarcoma. While early research suggested that the virus was transmitted sexually and that it was present only in KS patients, more recent studies seem to show that infection with the virus is more common than once thought, presenting differing distribution patterns in different geographical areas. In this study we analyze seroprevalence and transmission of HHV 8 in a sample of 86 family groups from Albania. Participants were selected among families requesting routine pre-expatriation medical examinations at the Poliambulatorio Padre "L. Monti" in Tirana. Specimens were collected from 180 healthy individuals and tested for the presence of a specific antibody. Antibody anti-HHV-8 detection was performed by immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA). The study found an overall rate of HHV 8 seroprevalence of 20.0%. In 4.5% of couples the male and female were both positive, in 30.2% at least one partner was positive; (in 17.4% only the male was positive; in 12.8% only the female). These results support the hypothesis that HHV 8 spreads via multiple transmission routes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578305

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  2 in total

Review 1.  Human herpesvirus 8--a novel human pathogen.

Authors:  Daniel C Edelman
Journal:  Virol J       Date:  2005-09-02       Impact factor: 4.099

Review 2.  Disseminated Kaposi sarcoma following COVID-19 in a 61-year-old Albanian immunocompetent man: a case report and review of the literature.

Authors:  Giulia Gardini; Silvia Odolini; Giovanni Moioli; Dorothea Angela Papalia; Vittorio Ferrari; Alberto Matteelli; Silvio Caligaris
Journal:  Eur J Med Res       Date:  2021-12-20       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.